Interaction Checker

Dasatinib : interactions médicamenteuses

Dasatinib (Sprycel, Phyrago) présente 152 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 69 de niveau majeur, 30 de niveau modéré, 53 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (69)

  • AmiodaroneantiarythmiqueMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Antiacides (Tums, Maalox, Mylanta)Produits sans ordonnanceMajeure

    Antacids: Avoid concomitant use. (notice Dasatinib, Interactions médicamenteuses)

  • Aprépitantinhibiteur du CYP3A4Majeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • AtazanavirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Bicarbonate de sodiumantiacideMajeure

    Antacids: Avoid concomitant use. (notice Dasatinib, Interactions médicamenteuses)

  • Bosentaninducteur du CYP3A4Majeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • CiclosporineimmunosuppresseurMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Majeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • ClobazambenzodiazépineMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • DarunavirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Darunavir et cobicistatantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Diltiazeminhibiteur calciqueMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • DronédaroneantiarythmiqueMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Érythromycineantibiotique macrolideMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • ÉtravirineantirétroviralMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Fluconazoleantifongique azoléMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • FosamprénavirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Fosaprépitantinhibiteur du CYP3A4Majeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • GriséofulvineantifongiqueMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Ibuprofène et famotidineAINSMajeure

    Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (notice Ibuprofène et famotidine, Interactions médicamenteuses)

  • Imatinibinhibiteur du CYP3A4Majeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • IsoniazideantibiotiqueMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Itraconazoleantifongique azoléMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Ivacaftorinhibiteur du CYP3A4Majeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Kétoconazoleantifongique azoléMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • LénacapavirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Lopinavir et ritonavirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Lorlatinibinducteur du CYP3A4Majeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Mifépristoneinhibiteur du CYP3A4Majeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Mirabégronagoniste bêta-adrénergiqueMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Mitapivatinducteur du CYP3A4Majeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Majeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Modafinilstimulant du SNCMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Nafcillineantibiotique de la famille des pénicillinesMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • NéfazodoneantidépresseurMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • NévirapineantirétroviralMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Oméprazole et bicarbonate de sodiuminhibiteur de la pompe à protons (IPP)Majeure

    Antacids: Avoid concomitant use. (notice Dasatinib, Interactions médicamenteuses)

  • OxcarbazépineanticonvulsivantMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Palbociclibinhibiteur du CYP3A4Majeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • PérampanelanticonvulsivantMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • PhénobarbitalbarbituriqueMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Phentermine et topiramatestimulant du SNCMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Posaconazoleantifongique azoléMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • PrimidoneanticonvulsivantMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Ranolazinemédicament allongeant l'intervalle QTMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • RifabutineantibiotiqueMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • RifampicineantibiotiqueMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • RifapentineantibiotiqueMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • RitonavirantirétroviralMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Suvorexantsédatif-hypnotiqueMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Suzétrigineinducteur du CYP3A4Majeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Ticagrélorantiagrégant plaquettaireMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • TopiramateanticonvulsivantMajeure

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (notice Dasatinib, Interactions médicamenteuses)

  • Vérapamilinhibiteur calciqueMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

  • Voriconazoleantifongique azoléMajeure

    Avoid concomitant use of strong CYP3A4 inhibitors. (notice Dasatinib, Interactions médicamenteuses)

Interactions modérées (30)

  • AdénosineantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • ApixabananticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • ArgatrobananticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • BivalirudineanticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • DabigatrananticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • Dexlansoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (notice Dexlansoprazole, Interactions médicamenteuses)

  • Digoxineglycoside digitaliqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • DisopyramideantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • DofétilideantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • ÉdoxabananticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • ÉnoxaparineanticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • EsmololbêtabloquantModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • Ésoméprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (notice Ésoméprazole, Interactions médicamenteuses)

  • FlécaïnideantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • FondaparinuxanticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • HéparineanticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • IbutilideantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • Lansoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (notice Lansoprazole, Interactions médicamenteuses)

  • Lidocaïneanesthésique localModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • Lidocaïne et prilocaïneanesthésique localModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • MexilétineantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • Oméprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (notice Oméprazole, Interactions médicamenteuses)

  • Pantoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (notice Pantoprazole, Interactions médicamenteuses)

  • ProcaïnamideantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • PropafénoneantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • QuinidineantiarythmiqueModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • Rabéprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (notice Rabéprazole, Interactions médicamenteuses)

  • RivaroxabananticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

  • SotalolbêtabloquantModérée

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (notice Dasatinib, Mises en garde et précautions)

  • WarfarineanticoagulantModérée

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (notice Dasatinib, Mises en garde et précautions)

Mentions mineures (53)

  • Acétazolamideinhibiteur de l'anhydrase carboniqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Amiloridediurétique épargneur de potassiumMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Aténolol et chlortalidonebêtabloquantMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Azélastine et fluticasoneantihistaminiqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • BéclométasonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • BétaméthasonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Bisoprolol et hydrochlorothiazidebêtabloquantMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • BudésonidecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Budésonide et formotérolcorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Bumétanidediurétique de l'anseMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Chlorothiazidediurétique thiazidiqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Chlortalidonediurétique thiazidiqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • CiclésonidecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • ClobétasolcorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • DéflazacortcorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • DésonidecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Éplérénoneantagoniste de l'aldostéroneMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • FludrocortisonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • FlunisolidecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • FluocinonidecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • FluticasonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Fluticasone et salmétérolcorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Furosémidediurétique de l'anseMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • HalobétasolcorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Hydrochlorothiazidediurétique thiazidiqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • HydrocortisonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Indapamidediurétique thiazidiqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • MéthylprednisolonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Métolazonediurétique thiazidiqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Métoprolol et hydrochlorothiazidebêtabloquantMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • MométasonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Olopatadine et mométasoneantihistaminiqueMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • PrednisolonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • PrednisonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Spironolactoneantagoniste de l'aldostéroneMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Torasémidediurétique de l'anseMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • TriamcinolonecorticoïdeMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Triamtérènediurétique épargneur de potassiumMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

Vérifiez Dasatinib avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.